8 résultats : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker

Attention : l'accès aux ressources peut être restreint, soit pour des raisons juridiques, soit par la volonté de l'auteur.
8 résultats
page 1 sur 1
résultats 1 à 8
Canal-U
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy GELLER, Bethesda, USA Abstract : Best statistical methods for evaluating the merits of a novel ma ...
Mots clés : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Date : 01-12-2012
Droits : Droits réservés à l'éditeur et aux auteurs.
 En savoir plus
 Description complète
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
 Ajouter à mon panier
Accéder aux documents
Canal-U
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates). Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy GELLER, Bethesda, USA Abstract : debate : Best statistical methods for evaluating ...
Mots clés : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Date : 01-12-2012
Droits : Droits réservés à l'éditeur et aux auteurs.
 En savoir plus
 Description complète
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).
 Ajouter à mon panier
Accéder aux documents
Canal-U
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures Speaker: Michael FELKER, Durham, USA Abstract : Biomarker guided-therapy: Are there other endpoints besides ...
Mots clés : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Date : 01-12-2012
Droits : Droits réservés à l'éditeur et aux auteurs.
 En savoir plus
 Description complète
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures
 Ajouter à mon panier
Accéder aux documents
Canal-U
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies? John JARCHO, Boston, USA, NEJM Rita REDBERG, San Francisco, ...
Mots clés : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Date : 01-12-2012
Droits : Droits réservés à l'éditeur et aux auteurs.
 En savoir plus
 Description complète
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
 Ajouter à mon panier
Accéder aux documents
Canal-U
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy GELLER, Bethesda, USA Abstract : Best statistical methods for evaluating the merits of a novel ma ...
Mots clés : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Date : 01-12-2012
Droits : Droits réservés à l'éditeur et aux auteurs.
 En savoir plus
 Description complète
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
 Ajouter à mon panier
Accéder aux documents
Canal-U
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied? Speaker: Jim JANUZZI, Boston, USA Discussant: James SNIDER, Critical Diagnostics, USA Abstract : How should Diagnostic and Prognostic Markers Be Studied? The measurement of ...
Mots clés : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Date : 01-12-2012
Droits : Droits réservés à l'éditeur et aux auteurs.
 En savoir plus
 Description complète
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
 Ajouter à mon panier
Accéder aux documents
Canal-U
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies? John JARCHO, Boston, USA, NEJM Rita REDBERG, San Francisco, ...
Mots clés : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Date : 01-12-2012
Droits : Droits réservés à l'éditeur et aux auteurs.
 En savoir plus
 Description complète
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
 Ajouter à mon panier
Accéder aux documents
Canal-U
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
Description : Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied? Speaker: Jim JANUZZI, Boston, USA Discussant: James SNIDER, Critical Diagnostics, USA Abstract : How should Diagnostic and Prognostic Markers Be Studied? The measurement of ...
Mots clés : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, biomarker
Date : 01-12-2012
Droits : Droits réservés à l'éditeur et aux auteurs.
 En savoir plus
 Description complète
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
 Ajouter à mon panier
Accéder aux documents